SCHEMBL5464861

SCHEMBL5464861

C=CCn1nc(Cl)c2cc(N)ccc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 2/20 0.39
▸ CNR2 P34972 2/20 0.39
▸ ACHE P22303 1/20 0.39
▸ EGFR P00533 1/20 0.37
▸ PDE4B Q07343 2/20 0.34
▸ PDE4D Q08499 2/20 0.34
▸ KDM4E B2RXH2 3/20 0.33
▸ ALDH1A1 P00352 3/20 0.33
▸ HPGD P15428 3/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ SMN1; SMN2 Q16637 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ SLC2A1 P11166 1/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ HBB P68871 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5464933 0.77 CNR2 (0.46) CNR1CNR2ACHEALDH1A1MAPT
SCHEMBL5443607 0.75 KDM4C (0.39) CNR1CNR2ACHEKMT2AGRM4
SCHEMBL5297088 0.74 CNR1 (0.49) CNR1CNR2ACHEKDM4EALDH1A1
SCHEMBL6069757 0.72 CNR2 (0.54) CNR1CNR2ACHEALDH1A1LMNA
SCHEMBL5437713 0.72 CNR1 (0.40) CNR1CNR2ACHEPDE4BPDE4D
SCHEMBL17417873 0.72 MAPT (0.50) EGFRKDM4EALDH1A1HPGDRAB9A
SCHEMBL4028459 0.71 CNR1 (0.49) CNR1CNR2ACHEKDM4EALDH1A1
SCHEMBL29200976 0.70 PRKCI (0.39) CNR1CNR2ACHEEGFRKDM4E
SCHEMBL5434835 0.70 CNR1 (0.51) CNR1CNR2ACHEEGFRALDH1A1
SCHEMBL18967662 0.70 KDM4E (0.34) EGFRKDM4EALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070265325-A1 Nitro Indazole Derivatives ASTRAZENECA AB (SE) 2007-11-15 — — US disclosed
US-20070265325-A1 Nitro Indazole Derivatives ASTRAZENECA AB (SE) 2007-11-15 — — US disclosed
US-20070265325-A1 Nitro Indazole Derivatives ASTRAZENECA AB (SE) 2007-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265325-A1 Nitro Indazole Derivatives NOS3, CYP3A43, NOS2 CNR1 155/4885CNR2 210/4885ACHE 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback